NCT00814021 2026-04-15
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Institut Claudius Regaud
Phase 2 Completed
Clinical Trials
26 trialsNCT06726421 2026-01-15
STROKER
Sun Yat-sen University
Phase 3 Recruiting
NCT03035630 2022-02-15
Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT02689167 2021-11-29
SURF
Centre Hospitalier Universitaire de Besancon
Phase 2 Unknown
NCT01185366 2021-04-28
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00853125 2021-04-27
Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00541008 2021-02-21
Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
UNICANCER
Phase 2 Completed
NCT02060370 2020-02-27
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03571438 2020-01-18
COMBOREIN
University Hospital, Grenoble
Phase NA Unknown
NCT03323710 2019-01-09
Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma
Military Institute od Medicine National Research Institute
Phase 2 Withdrawn
NCT01108445 2018-01-16
ASPEN
Duke University
Phase 2 Completed
NCT00537056 2017-06-14
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
Stanford University
Phase NA Completed
NCT00425386 2017-05-03
Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer
OHSU Knight Cancer Institute
Phase 2 Completed
NCT02446795 2017-01-18
QUASAR
Consorzio Oncotech
Phase 1/2 Unknown
NCT00943839 2016-11-10
Sunitinib Malate in Treating Patients With Kidney Cancer
Centre Antoine Lacassagne
Phase NA Completed
NCT00465179 2016-06-07
Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02688491 2016-02-25
A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment
First Affiliated Hospital, Sun Yat-Sen University
Phase NA Not yet recruiting
NCT00462982 2015-12-30
Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00459875 2015-11-26
Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01122615 2015-11-18
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00747305 2015-10-22
Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery
Medical University of South Carolina
Phase 1 Terminated
NCT00849186 2015-02-06
Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer
Roswell Park Cancer Institute
Phase NA Completed
NCT00459979 2014-03-07
Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01070186 2012-07-31
Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT00422344 2010-02-26
A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00421512 2008-11-11
A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients
Memorial Sloan Kettering Cancer Center
Phase 1 Completed